Tesamoreline

Tesamorelin (Egrifta SV, Egrifta WR)

Description: Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH), consisting of all 44 amino acids of human GHRH with an added trans-3-hexenoic acid group for enhanced stability and potency. It is FDA-approved for reducing excess abdominal fat (lipodystrophy) in HIV-infected adults. Tesamorelin stimulates the pituitary gland to release growth hormone (GH), which increases insulin-like growth factor-1 (IGF-1) levels, promoting lipolysis and reducing visceral fat. It is administered via subcutaneous injection, typically at a dose of 2 mg daily in the abdomen.

Uses: Primarily used to treat HIV-associated lipodystrophy by reducing visceral abdominal fat. Emerging research explores its potential in improving lipid profiles, glucose handling, cognitive function in individuals over 60, and conditions like non-alcoholic fatty liver disease (NAFLD/NASH). It may also support muscle growth and recovery in bodybuilding contexts, though this is not an FDA-approved use.

Dosage Forms: Available as a subcutaneous powder for injection (2 mg/vial or 11.6 mg/vial). Egrifta WR requires weekly reconstitution, while Egrifta SV is a daily formulation.

Administration: Injected subcutaneously once daily. Patients are instructed to rotate injection sites to prevent skin issues and avoid areas with scars, bruises, or the belly button. A healthcare provider will guide preparation and injection techniques for at-home use.

Storage: Store tesamorelin powder vials in the refrigerator (do not freeze). Diluent should be kept at room temperature, away from moisture, heat, and light. Discard unused vials after the expiration date. Egrifta WR vials (11.6 mg) can be stored at room temperature (68°F to 77°F).

Side Effects: Common side effects include joint pain, injection site redness, swelling, or itching. Serious risks include potential allergic reactions (rash, swelling, breathing difficulties), increased IGF-1 levels, glucose intolerance, and a possible increased risk of cancer or cancer reactivation. It may also cause injection site reactions like pain, bruising, or inflammation.

Contraindications: Not for use in patients under 18, pregnant women (category X, may harm fetus), or those with active or past cancer, hypothalamic-pituitary axis disruption, or allergies to tesamorelin or its ingredients. Use caution in patients with diabetes or scheduled heart/stomach surgery.

Precautions: Monitor blood sugar levels, as tesamorelin may affect glucose metabolism. Inform your doctor of all medications, including prescription, over-the-counter, vitamins, and herbal products, to avoid interactions. Regular blood tests may be required to check IGF-1 levels.

Availability: Available only by prescription in the U.S. Not approved in Europe. Manufactured by Theratechnologies Inc., Canada.

Note: For informational purposes only. Consult a healthcare provider for medical advice. Products are not intended for unapproved uses like bodybuilding without professional guidance.